ClinicalTrials.gg
TerminatedNCT04468373Updated Jul 13, 2020

Study of WA-NG (NG-IMT) Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration

An interventional study of WA-NG (NG-IMT) Telescope Prothesis in Age Related Macular Degeneration, sponsored by VisionCare, Inc.. Terminated at 2 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-07-13.

Sponsored by VisionCare, Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Development of next-generation device

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled May 2015, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Macular Degeneration by VisionCare, Inc. — 2 open to participants now, 3 under way, none of them phase 3. Macular Degeneration · VisionCare, Inc..

Enrollment
7th of 10
9 · median 31
Started
2015
the only one that year
No phase
9 of 10
2 open now
Registered
6th of 10
by date

Among the 10 studies in Macular Degeneration by VisionCare, Inc., this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 9 with no phase, and was the 6th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 10 studies in Macular Degeneration by VisionCare, Inc. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Macular Degeneration by VisionCare, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of the updated Model WA-NG telescope prosthesis (hereafter WA-NG telescope), an injectable telescope device, in patients with bilateral moderate to profound central vision impairment due to end-stage age-related macular degeneration.

Read the detailed description

Patients will be screened for eligibility and informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. Eligible patients will be examined preoperatively to obtain a medical history and to establish a baseline for ocular condition.

Postoperatively, patients will undergo ophthalmic evaluation at regular intervals as specified in this protocol.

03

Conditions studied

  • Age Related Macular Degeneration

Keywords

  • Macular Degeneration
  • Visual Impairment
  • Implantable Telescope
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

**The following Inc. \& Exc. are sample and not completed list **

Main Exclusion Criteria:

  • Patients with bilateral, stable, moderate to profound central vision impairment due to bilateral central scotoma associated with end-stage macular degeneration, defined as retinal findings of bilateral, geographic atrophy or disciform scar with foveal involvement.
  • Patients must have distance BCVA between 20/80 and 20/800, and adequate peripheral vision in one eye (the non-implanted eye) to allow navigation
  • Patients must achieve at least a five letter improvement on the ETDRS chart in the eye scheduled for surgery, with the external telescope simulator (ETS)
  • Patients must be available for the study duration of 12 months
  • Patients must be alert, mentally competent, and able to understand and comply with the requirements of the clinical trial, and be personally motivated to abide by the requirements and restrictions of the clinical trial.

Main Exclusion Criteria:

  • Evidence of active CNV on fluorescein angiography or treatment for CNV within the past six months.
  • Patients who may require fellow eye cataract extraction and intraocular lens implantation during the 12 months following WA-NG telescope implantation. If fellow eye cataract extraction is anticipated, this procedure should be performed at least 30 days prior to enrollment in the clinical study.
  • Patients who have had or are expected to have ophthalmic related surgery within the 30 days preceding implantation of the device.
  • Patients who have undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of surgery for either refractive or therapeutic purposes.
  • Patients participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    WA-NG (NG-IMT) Telescope Prothesis

    Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)

    Device: WA-NG (NG-IMT) Telescope Prothesis

Interventions

  • DeviceWA-NG (NG-IMT) Telescope Prothesis

    The WA-NG telescope prosthesis is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.

06

What researchers measure

Primary outcomes

  1. Positional stabilitytilt (the following parameter will be measured/ assessed :device centered (yes/ no) questionnaire)

    Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam) and anterior segment Ocular Coherence Tomography (OCT is a non-invasive imaging test )

    Time frame: 12 months

  2. Positional stabilitytilt, the following parameter will be measured/ assessed : tilted (° C)

    Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam) and anterior segment Ocular Coherence Tomography (OCT is a non-invasive imaging test )

    Time frame: 12 months

  3. Positional stabilitytilt , the following parameter will be measured/ assessed : malpositioned (yes/no) questionnaire

    Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam) and anterior segment Ocular Coherence Tomography (OCT is a non-invasive imaging test )

    Time frame: 12 months

  4. Positional stabilitytilt , the following parameter will be measured/ assessed : endothelial cell count (Cells/mm2))

    Time frame: 12 months

  5. Positional stabilitytilt , the following parameter will be measured/ assessed : Intraocular pressure (mmHg)

    Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam)

    Time frame: 12 months

  6. Number of Adverse events associated with the implant and use of the device will be evaluated.

    Time frame: 12 months

07

Study locations

2 sites
  • Mater Private Hospital
    Dublin, Ireland
  • VISSUM Ophthalmological Corporation
    Alicante, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2015 to primary completion in Jul 2020, 62 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2018
First posted
Jul 13, 2020
StartActual
May 2015
Primary completionActual
Jul 2020
CompletionActual
Jul 2020
Last update
Jul 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04468373
Lead sponsor
VisionCare, Inc.
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
May 2015
Primary completion
Jul 2020
Completion
Jul 2020
Last update
Jul 13, 2020

Study contacts

Diane Gordon
study director · VisionCare Ophthalmic Technologies

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion